Japan Could Become The First Country To Eradicate HIV

Updated Mar 7, 2025 | 05:00 PM IST

SummaryThe idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.
Japan Could Become The First Country To Eradicate HIV

Credits: Canva

Japan could become one of the first countries in the world to end the HIV epidemic, says the president of Gilead Sciences Japan, Kennet Brysting. The idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.

What Is The Role Of Preventative HIV Medicines?

Gilead's have two key drugs, Truvada and lenacapavir. These two are playing a crucial role in prevention. Truvada is taken as a daily pill, while lenacapavir requires two injections per year. It can make the virus undetectable in infected individuals and prevent transmission to those who are not infected yet. In trials, lenacapavir showed 100% efficacy in preventing HIV infections. This is why it is describe as "almost a vaccine".

In 2024, Japan also approved Truvada for HIV prevention, but the country has yet to approve lenacapavir for the same. Until now, people in Japan had been importing generic versions of Truvada or purchasing it from clinics that source it from overseas.

HIV In Japan

Up until now, Japan reported around 25,000 HIV infections, whereas 669 new cases were reported in 2023. For seven consecutive years, the number of new infections remained under 1,000. The downward trend thus shows that the virus has been controlled, however, getting to zero new infections remains the ultimate goal.

Brysting too acknowledged that simply having effective drug is not enough. What is important is to have a proper implementation, access and healthcare support to make sure that these treatments are widely available and effective.

What Are The Challenges In Implementation?

The biggest challenges is testing rates. There is a need to increase testing rates. At this very moment, around 86% people infective with Japan have been tested, but the goal is to increase it up to 95%, with an ideal goal of 100%. Without widespread testing, many infected people may not even know that they are infected and it could transmit the virus.

Another measure issue is the cost of preventative medication. While Japan's health insurance covers treatments for diseases, it does not cover preventative drugs. Those who purchase Truvada for prevention, pay around $470 per month. Some clinics in Tokyo offer generic alternatives too, which is cheaper, but they are not ideal.

Better Healthcare Support

Brysting expressed concern that individuals importing medications might not be consulting doctors regularly, which is essential for monitoring HIV status and overall health. Truvada users need to be tested for HIV initially and every three months, along with screenings for other infections and kidney function checks. Without proper medical supervision, there is a risk of misuse and inadequate protection.

Gilead is in discussions with Japanese authorities to improve access and insurance coverage for Truvada, and progress is being made. Japan has shown efficiency in approving critical medicines, as seen during the COVID-19 pandemic when Gilead’s remdesivir was approved in just three days.

What Is The Way Ahead?

Gilead at this moment is not only focused on HIV and hepatitis C, but also expanding into oncology with innovative treatments like CAR-T cell therapy, which strengthens a patient's immune system to fight cancer.

However, Japan’s strict approval processes can slow down drug availability. Phase 3 clinical trials often need to be conducted within the country, and Japan tends to approve medicines much later than other regions. For instance, Truvada was approved for prevention in Japan 12 years after the U.S. and nearly 20 years after its approval for treatment. inancial factors also play a role. The Japanese government adjusts drug prices annually, often reducing them, which can make long-term investment challenging for pharmaceutical companies.

End of Article

Is It Possible To 'Reset' Immune System? CAR-T Therapy Puts Woman With 3 Autoimmune Diseases Into Remission

Updated Nov 22, 2026 | 09:00 PM IST

SummaryA case published in the journal Med highlighted the potential of CAR-T therapy beyond cancer, especially in treating autoimmune diseases that do not respond to existing treatments.
Is It Possible To 'Reset' Immune System? CAR-T Therapy Puts Woman With 3 Autoimmune Diseases Into Remission

Credit: AI image

Autoimmune diseases are treated with therapies that suppress an overactive immune system that attacks the body’s healthy cells. So scientists are exploring if it is possible to ‘reset’ the immune system by removing the cells that attack the body.

A remarkable case from Germany may have made this possibility a reality. A 47-year-old woman suffering from three severe autoimmune diseases achieved remission after receiving a single infusion of experimental CAR-T cell therapy after years of unsuccessful treatments.

She no longer required daily blood transfusions and remained in remission nearly a year after therapy.

The case, published in the journal Med, highlighted the potential of CAR-T therapy beyond cancer, especially for severe autoimmune diseases that do not respond to existing treatment.

Woman Suffered From Three Autoimmune Diseases

Also read: 40-Year-Old Thought He Had Flu But It Was A Rare Autoimmune Disease Failing His Kidneys: What Is Goodpasture Syndrome

The woman had been living with three autoimmune conditions that caused her immune system to attack different components of her body.

  • Autoimmune haemolytic anaemia (AIHA): Her immune system destroyed her red blood cells, which resulted in severe anaemia and a need for frequent blood transfusions.
  • Immune thrombocytopenia (ITP): Her immune system attacked platelets, the blood components responsible for helping blood clot, increasing her risk of bleeding.
  • Antiphospholipid syndrome (APS): Her body produced antibodies linked with dangerous blood clots, which required her to be on blood-thinning medication.

She had been living with the conditions for more than a decade, and she had already undergone nine different treatments, including steroids, antibody therapies and immunosuppressive drugs, which did not offer any improvement.

Her illness had significantly affected her daily life, leaving her severely fatigued and unable to carry out normal activities.

CAR-T Therapy Helped Her Enter Remission

Also read: Christina Applegate Suspects Breast Implants May Have Caused MS-Like Symptoms: What Is the Condition?

CAR-T therapy involves collecting a patient's T cells, genetically modifying them to recognise a specific target and infusing them back into the body.

In this case, the researchers engineered the patient's T cells to target CD19, a protein found on B cells. B cells normally help protect the body by producing antibodies, but dysfunctional B cells can generate antibodies that mistakenly attack healthy tissues.

The engineered CAR-T cells were designed to eliminate these problematic B cells, allowing the immune system to rebuild its B-cell pool.

The patient began improving rapidly after treatment. Within seven days, she no longer required blood transfusions. Within approximately 25 days, her haemoglobin levels had returned to normal, her platelet counts stabilised and the antibodies related to the disease linked to blood clotting had fallen significantly. Her doctors reported complete remission across all three conditions.

What Is 'Immune Reset'?

Also read: Nick Jonas Opens Up About Living With Type 1 Diabetes For More Than 2 Decades: What Does It Entail

Immune reset is to essentially eliminate the dysfunctional immune cells responsible for driving disease rather than suppressing them.

After CAR-T treatment, the patient's B cells began returning approximately 322 days later. Most appeared to be naive B cells, meaning they had not previously been exposed to antigens and did not carry the same established immune memory of her autoimmune disease.

This suggests CAR-T therapy may have cleared the problematic B-cell population and allowed a new population to develop without immediately restarting the autoimmune attack.

Researchers believe this could offer something conventional therapies often struggle to do, which is prolonged remission without ongoing treatment.

Side Effects Of CAR-T Therapy

While the patient's response was remarkable, this is a single case report and cannot establish how effective or safe CAR-T therapy would be for a larger population.

CAR-T treatment can cause serious complications like cytokine release syndrome, neurological toxicity, infections and prolonged immune suppression.

Although the patient did not experience severe cytokine release syndrome or neurological toxicity, she had some abnormalities during follow-up.

Researchers are now investigating CAR-T therapy in several autoimmune conditions, including lupus, systemic sclerosis and inflammatory muscle diseases.

End of Article

Virginia Reports First Measles Death After Nearly 50 Years As Cases In The Us Near 6,000

Updated Nov 22, 2026 | 05:00 PM IST

SummaryVirginia state health department recently announced the a four-year-old child, who had tested positive for measles, became the state's first measles-related death.
Virginia Reports First Measles Death After Nearly 50 Years As Cases In The Us Near 6,000

Credit: AI image

Virginia reported a young child as its first case of measles-related death of 2026. Marking 48 years, the state had reported its last death due to measles in 1978.

According to the state’s health department, the child, who was four years old or maybe even younger, had tested positive for measles. The child’s vaccination status was not disclosed by the department, citing family privacy.

Virginia Reports First Measles Death After 48 Years

Also read: Measles Vaccine, Autism & Tylenol: RFK Jr's Most Controversial Health Claims

The latest Virginia fatality has added to the worst measles crisis the US is seeing in nearly three decades. The outbreak has cost the US its measles elimination status after the country maintained it for 26 years.

Virginia has reported 220 measles ⁠cases so far in 2026. It includes 40 among children aged four years old or younger and 75 among those age five to 12, according to the state ⁠health department’s data.

Among those cases, 179 are in unvaccinated individuals, 39 among people ‌whose vaccination status was unknown and two in vaccinated individuals. This highlights the alarming decline in measles vaccination coverage across the country, which has fueled sustained transmission of the disease.

Frederic Bertley, immunologist and chief executive officer of the Center of Science and Industry said, “Virginia has not had a measles-related death ‌since 1978.”

Bertley also said that the measles virus is both alarming and evidence that measles is becoming a growing problem for the US.

Virginia health officials have reported an increase in measles cases largely ‌in the state’s central region. Buckingham county has reported 127 cases, the most in the state, while neighboring Charlotte county has recorded 34 cases.

Measles Deaths And Cases In The US

Also read: Why Has CDC Challenged The Report Of Two Measles Deaths In Pennsylvania?

Virginia’s first measles-associated death has taken the national toll to 12. This comes days after US, Mexico, and Bolivia lost their measles elimination status.

Pennsylvania, the worst-hit state in the measles outbreak, has reported 12 deaths. Wisconsin, on the other hand, has had two deaths. New York reported its first measles-related death in 30 years.

The U.S. Centers for Disease Control and Prevention has reported more than 5,800 cases nationally in 2026, by far the most of any year since 1991.

Who Needs A Booster Measles Vaccine Dose?

Also read: EXCLUSIVE: Ex-CDC Vaccine Advisor Says Measles Outbreak Bigger Than Reported, Slams RFK Jr’s ‘No-See Evil’ Approach

According to the US Centers for Disease Control and Prevention (CDC), adults born in 1957 or later who do not have evidence of immunity should receive at least one dose of the MMR vaccine. But certain groups are recommended to receive two doses, separated by at least 28 days. These include:

  • Healthcare workers: Those who are exposed to infected patients and could transmit the virus to vulnerable individuals.
  • International travellers: People travelling to countries where measles transmission is occurring.
  • College and university students: Students who may be exposed in crowded environments.
  • People living with immunocompromised individuals: Close contacts of people with weakened immune systems who may be unable to receive live vaccines themselves.
  • People living with HIV: Those who do not have severe immunosuppression and lack of measles immunity.
  • People in outbreak-affected areas: Adults advised to receive a second dose because of increased exposure.

People who have received two documented doses of the MMR vaccine, with the first administered at or after 12 months of age and the doses appropriately spaced, are considered protected for life.

End of Article

Changes In Speech, Pauses & Word Choice May Help Detect Alzheimer's Early; Bill Gates Calls Research 'Fascinating'

Updated Nov 22, 2026 | 07:21 PM IST

SummaryIn a research led by Dr. Marziye Eshghi from Mass General Brigham University of Health Professions in Boston, analysis of speech changes identified patients at risk of Alzheimer's accurately up to 77% of the time.
Changes In Speech, Pauses & Word Choice May Help Detect Alzheimer's Early; Bill Gates Calls Research 'Fascinating'

Credit: AI image

Speech is “really a window into brain health”, said Dr. Marilu Gorno Tempini, director of the language neurobiology laboratory at the University of California, San Francisco. The neuroscientist used the phrase while talking about developments in research related to changes in speed and dementia risk.

Described as one of the most “fascinating fields of research” by billionaire tech entrepreneur Bill Gates, speech patterns, including pauses while speaking, speaking speed, choice of words, vocabulary and sentence structure, are being studied to identify early changes in brain health.

In an X post, Gates wrote, "It turns out that speech may be a window into brain health and Alzheimer’s risk. To me, it’s one of the most fascinating fields of research right now."

Speech is a complex brain activity, which entails processing language, vocabulary, retrieving memories, focusing and paying attention. Changes in any of these activities could indicate a person’s cognitive decline and their risk of developing neurodegenerative disorders like Alzheimer’s.

Technological advances in artificial intelligence have made it possible to analyse speech patterns that could be recorded in everyday communications.

Also read: Experimental Alzheimer's Drug Slows Cognitive Decline By 38% In A Two-Year Trial: How Does It Work?

Changes In Speech Patterns And Alzheimer’s Risk

Due to developments in the field, it has become feasible for researchers to analyse speech-related changes that reflect cognitive health.

People can record themselves, producing useful data that can be combined with brain imaging and blood tests, could be used to predict dementia risk and monitor progression of cognitive impairment.

Marziye Eshghi from Mass General Brigham University of Health Professions in Boston is leading the research in the area. She said, “We are seeing differences that humans can’t see or can’t really detect by their ears, but it’s there years and years before cognitive decline.”

Also read: 'Viagra For The Brain': New Pill Slows Decline in Memory, Thinking By 31% In Some Alzheimer's Patients

Dr. Eshghi’s project is based on 130 different speech-related features in participants. The data is then processed through artificial intelligence algorithms and compared to established biological risk factors for Alzheimer’s disease.

After the preliminary results came out, it was observed that speech-related data was better than cognitive testing at identifying Alzheimer’s risk in cognitively unimpaired older people.

“What we are doing is capturing individuals who are at higher risk of developing Alzheimer’s disease, but they are still not showing any symptoms,” said Dr. Eshghi.

Speech analysis could also help researchers determine those at greater risk among people who have tested positive for Alzheimer’s biomarkers, Melissa Lee, who directs digital and A.I. at the nonprofit Alzheimer’s Drug Discovery Foundation, told New York Times.

She said, “If we have two people with positive blood tests, one shows decline and one won’t, and we’d use their speech to tell them apart.”

Also read: Can Unhappy Marriages Increase Dementia Risk? Study Finds 38% Chance

Speech Analysis Identified Patients At Risk Of Alzheimer’s Up To 77% Of The Time

In one of the studies, 49 people without cognitive impairment were classified as low-risk, moderate-risk or high-risk based on levels of an Alzheimer’s-related protein in their blood and whether they had a genetic variant commonly observed with increased risk.

Researchers then analyzed speech recordings, without knowing participants’ risk categories, and tested whether a computer model could determine which participants were in which group.

In preliminary results, the speech-based analysis classified participants accurately up to 77 percent of the time. This fared much better than the 47 percent accuracy of common cognitive testing models.

Changes in speech pattern may also be used in analysing other health conditions like depression, Parkinson’s disease, and diabetes. These three conditions are often accompanied with subtle changes in voice like talking speed, slurred speech, and vocal hoarseness.

End of Article